These include (i) release of p53 from mortalin-p53 complexes in cancer cells, (ii) activation of nuclear translocation and reactivation of p53 activities including execution of DNA damage response, growth arrest and apoptosis and (iii) specific targeting of p53Y220C and conformational reconstitution of its wild type functions. The gene discussed is HSPA9; the disease is cancer.